Welcome to our dedicated page for CRESCO LABS news (Ticker: CRLBF), a resource for investors and traders seeking the latest updates and insights on CRESCO LABS stock.
Cresco Labs Inc. reports developments in branded cannabis products, retail dispensaries, cultivation, production and state-regulated market access. The company operates Sunnyside dispensaries and distributes cannabis brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s and Remedi.
Recurring updates cover quarterly financial results, dispensary openings, medical and adult-use market activity, cannabis licensing matters and operational growth initiatives. Company communications also address branded product distribution, retail execution, balance sheet and cash-flow themes, community outreach, workforce development and legislative or regulatory engagement in the cannabis industry.
Cresco Labs (OTCQX: CRLBF) held its annual general and special meeting of shareholders on September 16, 2025, where several key corporate governance matters were approved with overwhelming shareholder support of at least 96% for each item.
Shareholders approved fixing the board size at seven directors and elected all nominated directors including Charles Bachtell, Gerald F. Corcoran, Robert M. Sampson, Thomas J. Manning, Marc Lustig, Michele Roberts, and Randy D. Podolsky. Baker Tilly US, LLP was appointed as the company's auditor.
Additionally, shareholders approved an Award Exchange Program allowing certain employees to exchange underwater options for full value awards with new three-year vesting terms, aimed at better aligning employee compensation with shareholder interests.
Cresco Labs (OTCQX:CRLBF) has announced the opening of a new Sunnyside dispensary in Proctorville, Ohio, marking its sixth location in Ohio and 71st nationwide. The strategic location at 200 State Street is significant as it's the only dispensary within a 45-mile radius.
The expansion aligns with Cresco's market leadership, as the company currently holds the number one position in retail market share and ranks third in branded product share in Ohio. The company plans to open two more dispensaries in Ohio in the coming months, further strengthening its presence in the state.
Cresco Labs (OTCQX:CRLBF) has successfully closed a $325 million senior secured term loan refinancing, replacing its previous $360 million facility. The new loan features a 12.5% annual interest rate and extends maturity to August 13, 2030.
The refinancing strengthens the company's balance sheet by reducing total debt and provides enhanced flexibility to prepay up to $125 million at a reduced premium. The facility contains no equity or convertible features and includes standard financial and operational covenants.
Cresco Labs (OTCQX:CRLBF) reported solid Q2 2025 financial results with revenue of $164 million and Adjusted EBITDA of $41 million, maintaining a 25% EBITDA margin. The company generated $9 million in operating cash flow and achieved a gross margin of 50.6%.
A significant milestone includes securing a commitment letter for a new $325 million term loan to refinance existing debt, strengthening the company's balance sheet and financial flexibility. The quarter saw a net loss of $14 million, which includes $9 million in non-cash impairment charges related to California assets.
The company maintained its #1 market share position in multiple billion-dollar markets while positioning itself for strategic M&A opportunities in the consolidating cannabis industry.
Cresco Labs (OTCQX: CRLBF) has secured commitments to refinance its senior secured credit facility with a new $325 million term loan. The new facility, maturing in 5 years, will replace the existing $360 million credit facility and carries a 12.5% annual interest rate.
The refinancing includes provisions allowing prepayment of up to $125 million at a reduced premium. This strategic move comes amid constrained capital access in the U.S. cannabis sector, with approximately $2 billion in industry debt maturing in the next 18 months. The transaction is expected to close around August 13, 2025.
Cresco Labs (OTCQX:CRLBF) has announced plans to divest its California operations as part of a strategic restructuring initiative. The company will sell its cultivation, manufacturing, and select distribution operations in California while retaining ownership of its premium FloraCal® brand.
The decision comes as Cresco Labs aims to strengthen its balance sheet and increase cash flow by focusing on markets with higher margins and better growth potential. CEO Charlie Bachtell cited structural challenges in California's cannabis market, including fragmented retail, price compression, and illicit market competition, as key factors making sustainable profitability difficult to achieve.
The transaction is expected to close within the next several quarters, subject to regulatory approvals and customary closing conditions.
Cresco Labs (OTCQX:CRLBF), a leading branded cannabis products company and operator of Sunnyside dispensaries, has scheduled its Second Quarter 2025 earnings release for August 7, 2025, before market opening.
The company will host a conference call and webcast at 8:30 am ET to discuss financial results and business highlights. Investors can access the call through US toll-free (1-833-470-1428) or US local (1-404-975-4839) numbers using access code 158138. The webcast recording will be available for one year on Cresco's investor relations website.
Cresco Labs (CRLBF) has announced an updated schedule for its first quarter 2025 earnings release. The company will file its Q1 interim financial statements and MD&A on Friday, May 30, 2025. Following a three-week review period with independent auditors, Cresco confirmed no material changes were found from the preparation made for May 9th.
The earnings conference call and webcast is scheduled for Monday, June 2, 2025, at 8:30 am ET. The webcast recording will be accessible for one year through Cresco Labs' investor relations website.